Should aspirin (acetylsalicylic acid) be discontinued in patients undergoing below-knee amputation (BKA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 6, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Research

Aspirin should generally not be discontinued in patients undergoing below-knee amputation (BKA) unless there are specific contraindications or high bleeding risk factors. For patients already on aspirin therapy for cardiovascular disease prevention or other indications, it is typically recommended to continue the medication through the perioperative period. The standard dose of 81-325 mg daily can usually be maintained. This recommendation is based on the understanding that the thrombotic risk of discontinuing aspirin often outweighs the bleeding risk, particularly in vascular patients who commonly require BKA. Patients undergoing BKA frequently have underlying peripheral arterial disease and other cardiovascular comorbidities that benefit from continued antiplatelet therapy, as supported by studies such as 1 which found that pre- and postoperative aspirin usage was associated with increased two-year secondary prosthetic graft patency. The surgical team should be informed about the patient's aspirin use, and hemostasis should be carefully monitored during and after surgery. In cases where bleeding risk is exceptionally high, a brief interruption of 3-7 days before surgery may be considered, but this decision should be individualized based on the patient's specific thrombotic and bleeding risk profile, considering the findings of studies like 2 which highlighted the increased risk of major hemorrhagic events with the addition of warfarin to aspirin. Resumption of aspirin should occur as soon as hemostasis is achieved postoperatively, typically within 24 hours after surgery, aligning with the safety and efficacy profile of aspirin as demonstrated in recent research such as 3.

Key considerations include:

  • The patient's specific thrombotic and bleeding risk profile
  • The presence of any contraindications to aspirin use
  • The need for careful monitoring of hemostasis during and after surgery
  • The potential benefits of continuing aspirin therapy for patients with underlying cardiovascular comorbidities
  • The importance of individualizing the decision to interrupt aspirin therapy, if necessary, based on the patient's unique risk factors and clinical circumstances, as informed by studies such as 4 and 5.

Related Questions

What is the recommended prehospital chewable aspirin loading dose for an adult with suspected acute coronary syndrome, and what are the contraindications?
What are the recommended aspirin doses for acute coronary syndrome, secondary prevention after myocardial infarction, and primary prevention in high‑risk patients?
What is the recommended aspirin regimen for a patient presenting with chest pressure suggestive of acute coronary syndrome, including dosing and contraindications?
What is the recommended discharge plan for patients post myocardial infarction (MI)?
What is the immediate management for a patient presenting with anterolateral ischemia?
What is the most appropriate next step for a 6-year-old girl presenting with fever, runny nose, cough, hyperthermia (temperature of 102.2), tachycardia (heart rate of 130), tachypnea (respirations of 38), hypotension (blood pressure of 60/30), and hypoxemia (oxygen saturation of 94% on room air) with lethargy and ronchi in the left lung?
Can pulmonary embolism (PE) cause lactic acidosis?
When do patients undergo a mono-phase, bi-phase, or tri-phase computed tomography (CT) abdominal scan?
In a patient with basilar artery near total occlusion and a history of Atrial Fibrillation (AFib), is a Direct Oral Anticoagulant (DOAC) or Dabigatran (Pradaxa) better for long-term management?
What are the indications for biventricular pacemaker (BivP) implantation in patients with bradycardia and left ventricular (LV) systolic dysfunction?
What are the risks and benefits of statin therapy in patients at high risk of cardiovascular events?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.